Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
(CNBC, 2025-11-12T16:43:37Z)